Lotronex

Lotronex is a brand name of alosetron, approved by the FDA in the following formulation(s):

LOTRONEX (alosetron hydrochloride - tablet; oral)

• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: February 9, 2000
  
  Strength(s): EQ 1MG BASE ^[RLD]


• 
  Manufacturer: PROMETHEUS LABS
  
  Approval date: December 23, 2003
  
  Strength(s): EQ 0.5MG BASE
  

Has a generic version of Lotronex been approved?

No. There is currently no therapeutically equivalent version of Lotronex available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Lotronex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Tetrahydro-1H-pyrido[4,3-b]indol-1-one derivatives
  Patent 5,360,800
  Issued: November 1, 1994
  Inventor(s): Coates; Ian H. & North; Peter C. & Oxford; Alexander W.
  Assignee(s): Glaxo Group Limited
  The invention relates to tricyclic lactams of the general formula (I) ##STR1## wherein Im represents an imidazolyl group of the formula: ##STR2## and R.sup.1 represents a hydrogen atom or a group selected from C.sub.1-6 alkyl, C.sub.3-6 alkenyl, C.sub.3-10 alkynyl, C.sub.3-7 cycloalkyl, C.sub.3-7 cycloalkylC.sub.1-4 alkyl, phenyl, phenyl C.sub.1-3 alkyl, phenylmethoxymethyl, phenoxyethyl or phenoxymethyl, one of the groups represented by R.sup.2, R.sup.3 and R.sup.4 is a hydrogen atom or a C.sub.1-6 alkyl, C.sub.3-7 cycloalkyl, C.sub.3-6 alkenyl, phenyl or phenyl C.sub.1-3 alkyl group, and each of the other two groups, which may be the same or different, represents a hydrogen atom or a C.sub.1-6 alkhyl group; n represents 2 or 3; and physiologically acceptable salts and solvates thereof. The compounds are potent and selective antagonists of the effect of 5-HT at 5-HT.sub.3 receptors and are useful, for example, in the treatment of psychotic disorders, anxiety, and nausea and vomiting.
  
  Patent expiration dates:
  
  
  • January 13, 2013
    
    ✓ 
    Patent use: FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  



• 
  Medicaments for the treatment of non-constipated female irritable bowel syndrome
  Patent 6,284,770
  Issued: September 4, 2001
  Inventor(s): Mangel; Allen Wayne & Northcutt; Allison Ruth
  Assignee(s): Glaxo Wellcome Inc.
  This invention relates to the use of 5-HT3 receptor antagonists in the treatment of nonconstipated female IBS patients.
  
  Patent expiration dates:
  
  
  • October 5, 2018
    
    ✓ 
    Patent use: FOR WOMEN WITH SEVERE DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME (IBS)
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 1, 2011 - ONCE DAILY DOSING REGIMEN FOR PATIENTS WHO BECOME CONSTIPATED ON TWICE DAILY REGIMEN
  
  

See also...

• Lotronex Consumer Information (Drugs.com)
• Lotronex Consumer Information (Wolters Kluwer)
• Lotronex Consumer Information (Cerner Multum)
• Lotronex Advanced Consumer Information (Micromedex)
• Lotronex AHFS DI Monographs (ASHP)
• Alosetron Consumer Information (Wolters Kluwer)
• Alosetron Consumer Information (Cerner Multum)
• Alosetron Advanced Consumer Information (Micromedex)
• Alosetron Hydrochloride AHFS DI Monographs (ASHP)